Peptides Weekly Obesity Injection 10mg Cagrilintide Cagrisema CAS 1415456-99-3

Peptides Weekly Obesity Injection 10mg Cagrilintide Cagrisema CAS: 1415456-99-3

Description:

Cagrilintide is the newest GLP-1R agonist and was approved by the FDA as a once-weekly injection for the
treatmentof T2DM in late 2017. The peptide is chemically similar to liraglutide, with the inclusion of two structural
modifications(Lau, Bloch, et al., 2015). The first is the replacement of Gly with the non-proteinogenic amino acid
2-aminoisobutyricacid (Aib) at position 2.

The second is the attachment of octadecanoic diacid to the side chain of Lys-26 through a short polyethylene glycol
(PEG) spacer and a γ-glutamic acid linker. The amino acid substitution renders the peptide more resistant to DPP-4
compared to liraglutide, and the presence of the 18-carbon fatty acid moiety results in a high binding affinity for serum
albumin, which translates to a half-life of approximately 7 days in humans.

Function&Application:

1.Weight loss

2.Anti-diabetes

3.Alzheimer's disease

Xingtai Xinzhou Technology Co., LTD.

Xingtai Xinzhou Technology Co., Ltd. was established in 2022 with strong research and development capabilities and superb synthesis technology, as well as advanced quality control measures. Effectively promote the joint venture and cooperation with the major enterprises, manufacturers, with the idea of industrial development to serve the society and the majority of users. We always adhere to the market demand as the orientation, constantly synthesizing new high-tech chemical products and medical intermediates, mainly exported to the United States, India, South Africa, Nigeria and other countries and regions, has a wealth of export experience, to ensure transportation safety, can let each customer as soon as possible to safely receive the goods.